الفهرس 
HypertensionOnly 14 pages are availabe for public view
 |  | from | 227 |  |  |
| | | from | 227 | | |
Abstract
The aim of the present work is to highlight the potential protective
effect of sacubitril/valsartan and liraglutide on cardiac dysfunction in
DOCA induced hypertension in rats.
Hypertension was induced in male albino rats by injection of
DOCA 50 mg/kg once/week SC in 0.3 ml olive oil and NaCl (1%) in
drinking water for 3 weeks. Rats were divided into six groups: three
control groups (normal, sacubitril/valsartan and liraglutide control), and
three hypertensive groups (DOCA, DOCA+sacubitril/valsartan and
DOCA+liraglutide).
Sacubitril/valsartan 60 mg/kg/day orally, and liraglutide 0.3
mg/kg/day SC for 3 weeks were administered to study their effects on
blood pressure (systolic, diastolic and mean arterial pressure), heart rate,
body weight, blood glucose, serum N-terminal pro brain natriuretic
peptide (NT pro BNP) and serum (ROCK1) in deoxycorticosterone
(DOCA) salt hypertensive rats. Histopathological analysis of cardiac
tissue was also performed.
The present study revealed that DOCA induced hypertension led to
significant increase in SBP, DBP and MAP by 66.8%, 39.3% and 50.8%
respectively and significant decrease in heart rate by 10.2%.
The present work proved that sacubitril/valsartan treatment
significantly decreased SBP, DBP and MAP by 18.3%, 16.2% and 17.3%
respectively, while liraglutide significantly decreased SBP, DBP and
MAP by 13.8%, 14.6% and 14.3% respectively. As regards the heart rate,
sacubitril/valsartan significantly increased heart rate by 9.2% while the
heart rate is significantly increased by 11.2% with liraglutide.
DOCA led to a significant increase in blood glucose level by
26.8%. Treatment with sacubitril/valsartan significantly decreased blood
glucose level by 17.9% while liraglutide treatment significantly decreased
blood glucose by 34.4%.
DOCA induced hypertension led to a significant increase in serum
NT pro BNP by 34%. Sacubitril/valsartan significantly decreased NT pro
BNP by 22.8% and liraglutide decreased it by 10.1%.
Serum Rho- kinase (ROCK1) enzyme was increased significantly
in DOCA hypertensive group by 49.7%. Treatment with
Sacubitril/valsartan and liraglutide significantly decreased serum ROCK1
by 15.5% and 24.4% respectively.
Histopathological examination by light microscopy using
hematoxylin and eosin revealed irregular arrangement, marked
connective tissue, congestion, and inflammatory cells in DOCA group.
Sections stained by Masson's trichrome showed marked interstitial
fibrosis in the DOCA group which was ameliorated with
sacubitril/valsartan and to a lesser extent with liraglutide treatment.
Key words: DOCA, hypertension, NT pro BNP, ROCK1,
Sacubitril/valsartan and liraglutide